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A B S T R A C T
Alzheimer’s disease (AD) is a neurodegenerative disorder in which there is a decline of cholinergic func-
tion. The symptomatic AD treatment involves the use of ChEIs (cholinesterase inhibitors) as rivastigimine,
a dual inhibitor. The human butyrylcholinesterase (BChE) is an enzyme that has speciﬁc roles in cholin-
ergic neurotransmission and it has been associated with AD. In the serum, BChE is found in four main
molecular forms: G1 (monomer); G1-ALB (monomer linked to albumin); G2 (dimer); and G4 (te-
tramer). The interaction between the products of BCHE gene and CHE2 locus results in CHE2 C5+ and CHE2
C5- phenotypes. CHE2 C5+ phenotype and BChE-K are factors that inﬂuence on BChE activity. This work
aimed to verify the proportions of BChE molecular forms, total and relative activity in 139 AD patients
and 139 elderly controls, taking into account K variant, CHE2 locus, rivastigmine treatment and clinical
dementia rating (CDR) of AD patients. Phenotypic frequencies of CHE2 C5+ and frequency of the carriers
of the K allele were similar between groups. Total BChE activity in plasma was signiﬁcantly lower in AD
patients than in elderly controls. Furthermore, we found that reduction on plasma BChE activity is as-
sociated directly with AD progression in AD patients and that rivastigmine treatment has a stronger effect
on BChE activity within the CDR2 group. The reduction in BChE activity did not occur proportionally in
all molecular forms. Multiple regression analysis results conﬁrmed that AD acts as the main factor in
plasma BChE activity reduction and that severe stages are related with an even greater reduction. These
ﬁndings suggest that the reduction of total plasma BChE and relative BChE molecular forms activity in
AD patients is probably associated with a feedback mechanism and provides a future perspective of using
this enzyme as a possible plasmatic secondary marker for AD.
© 2014 Elsevier Ltd. All rights reserved.
1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder and the
most common cause of dementia. It is characterized pathological-
ly by the presence of amyloid plaques and neuroﬁbrillary tangles
in the brain besides decline of cholinergic function. The choliner-
gic deﬁcits in AD are strongly correlated with cognitive impairment
(Roberson and Harrell, 1997) which led to the formulation of the
“cholinergic hypothesis” (Davies and Maloney, 1976). This hypoth-
esis states that the inability to transmit neurologic impulses across
brain synapses is the cause of cognitive, global, and behavioral dys-
functions associated with dementia (Ladner and Lee, 1998).
Cholinesterases (ChE) are a family of enzymes that catalyze the
hydrolysis of acetylcholine (ACh) into choline and acetic acid, an es-
sential process for the restoration of the cholinergic neuron. There
are two cholinesterase types: acetylcholinesterase (AChE; EC 3.1.1.7)
and butyrylcholinesterase (BChE; EC 3.1.1.8). Both enzymes partic-
ipate in cholinergic neutrotransmission by hydrolyzing acetylcholine
in the central and peripheral nervous systems (Pohanka, 2011).
Based on cholinergic deﬁcits in AD, cholinesterase inhibitors
(ChEIs) are the ﬁrst-line drugs in the symptomatic treatment of AD
by inhibiting cholinesterase and thus resulting in increased syn-
aptic levels of acetylcholine neurotransmitter. Currently the most
prescribed ChEIs are donepezil, galantamine and rivastigmine. These
drugs are commonly used to treat patients with mild-to-moderate
AD (Qaseem et al., 2008) although Ferris et al.’s (2013) post-hoc anal-
ysis reinforces that rivastigmine may be an effective therapy in the
treatment of severe AD. Individual ChEIs differ from each other with
respect to their pharmacologic properties. Donepezil and galantamine
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are short-acting reversible competitive inhibitors, whereas
rivastigmine is actively metabolized by cholinesterase, thus making
it an intermediate-acting or ‘pseudo-irreversible’ inhibitor with an
intermediate duration of action (Jann et al., 2002). Although the
primary target of these agents is acetylcholinesterase (donepezil and
galantamine), rivastigmine shows equal aﬃnity for both AChE and
BChE enzymes (Jann et al., 2002). These agents do not stop disease
progression, but clinical studies have shown that they temporari-
ly stabilize cognitive impairment and help to maintain global
function, often delaying the need for patient placement in nursing
homes by several months (Michaelis, 2003).
Human butyrylcholinesterase (BChE; EC 3.1.1.8) is the second-
ary acetylcholine (ACh)-hydrolyzing enzyme encoded by the BCHE
gene (3q26.1-q26.2) (Arpagaus et al., 1990) and it is found in the
neuroﬁbrillary tangles and amyloid plaques of AD (Gómez-Ramos
and Morán, 1997), which suggests that it functions as a potential
modulator in the process. BChE is synthesized in the liver and dis-
tributed to several parts of the organism, including brain (Wescoe
et al., 1947). The butyrylcholinesterase activity is increased in elderly
brain (60–90 years) (Perry et al., 1978) and in AD patients’ brain,
mainly in the hippocampus and temporal cortex, suggesting a re-
lationship with the loss of episodic memory in AD (Arendt et al.,
1992; Perry et al., 1978) and cognitive decline in dementias (Perry
et al., 2003), respectively. Acetylcholinesterase (AChE) activity,
however, is reduced in AD brain and there was no correlation
between age and AChE activity (Perry et al., 1978). Studies suggest
that BChE may participate in the transformation of beta-amyloid
(Aβ) from an initially benign form to an eventually malignant form
associated with neuritic tissue degeneration and clinical demen-
tia (Darvesh et al., 2011; Guillozet et al., 1997). However, other
researchers found that BChE attenuates amyloid ﬁbril formation and
its presence in amyloid plaques implies that this enzyme incorpo-
rates into Aβ ﬁbrils at a late phase of their formation (Diamant et al.,
2006; Podoly et al., 2010).
In the serum, BChE is found in four molecular forms: G1
(monomer); G1-ALB (monomer linked to albumin); G2 (dimer) and
the most common form, G4 (tetramer) (Masson, 1979). The inter-
action between BChE tetramer and a protein encoded by CHE2 locus
(2q33-35) results in a complex named C5 band, identiﬁed in elec-
trophoresis only in 10.3% of a Southern Brazilian population
(Chautard-Freire-Maia et al., 1991). The CHE2 C5+ and CHE2 C5− phe-
notypes correspond to the presence and absence of the band,
respectively (Harris et al., 1962). CHE2 C5+ individuals have BChE
activity approximately 30% higher than CHE2 C5− individuals
(Chautard-Freire-Maia et al., 1991). Over 65 genetic variants were
described for the BCHE gene (Souza et al., 2005), and the K variant
(BChE-K; 1615A; rs1803274) is the most studied as a risk factor for
AD and it was primarily associated with 33% reduction of BChEmol-
ecules in plasma (Rubinstein et al., 1978).
Considering the debate about the change in BChE expression and
hydrolytic activity and the role on AD neuropathology, this work
aims to verify the proportions of BChE molecular forms (G1, G1-
ALB, G2 and G4), total and relative activities in AD patients and
elderly controls, taking into account K variant and CHE2 locus. More-
over, this study has the purpose to assess the total and molecular
forms activity of butyrylcholinesterase in AD patients treated and
not treated with rivastigmine at different stages of the disease.
2. Materials and methods
2.1. Sample
Blood samples were collected from 139 patients with Alzheim-
er’s disease from the Clinical Hospital of the Federal University of
Paraná (HC-UFPR) and Curitiba Neurology Institute (INC); and 139
elderly controls cognitively healthy, both groups constituted mainly
of euro-Brazilian from Southern Brazil. The present work was de-
signed as a case–control study and both groups were paired for sex,
age and years of schooling. Other forms of dementia have been ex-
cluded in the patient group with AD. All subjects read, accepted and
signed the term of informed consent. This study was previously ap-
proved by the ethical committee from HC-UFPR under registration
1192.117.11.08. The AD patients were diagnosed according to the
NIA-AA (National Institute on Aging and Alzheimer’s Association)
criteria for probable AD (McKhann et al., 2011). Clinical Dementia
Rating (CDR) originally developed by Hughes et al. (1982) and
adapted by Morris (1993) was used to classify the degree of de-
mentia in mild (CDR1), moderate (CDR2) and severe (CDR3). The
mini-mental state examination (MMSE) is a screening test that was
used to detect cognitive impairment in patients and controls. It was
originally published by Folstein et al. (1975) and the Portuguese
version used in the present study was developed by Bertolucci et al.
(1994). The control group was screened by neuropsychological tests
and submitted to an evaluation of impairment of daily activities,
and then selected according to reference values for the correspond-
ing age group.
2.2. Laboratory analysis
The samples were coded and processed to obtain the plasma.
Plasma BChE activity was measured using propionylthiocholine as
substrate at 25 °C as the protocol of Dietz et al. (1972) modiﬁed by
Evans and Wroe (1978). CHE2 locus phenotypes were identiﬁed by
acid agar gel electrophoresis (pH: 6.50) (Van Ros and Vervoot, 1973).
The detection of BChE bands in plasma was made according to
Boberg et al. (2010). Relative Intensity (RI) of each band was mea-
sured using KODAK 1D Image Analysis Software produced by KODAK,
and the relative activity (RA) of each band (G1, G1-ALB, G2 and G4)
was the result of multiplication of total BChE plasma activity by the
RI of each band detected in the polyacrylamide gel. DNA extrac-
tion was performed by a salting-out method (Lahiri and Nurnberger,
1991) and then diluted to a ﬁnal concentration of 20 ng/μL.
Genotyping of K variant (rs1803274) was obtained by TaqMan SNP
Genotyping Assay produced by Life Technologies according to
Simão-Silva et al. (2013).
2.3. Statistical analysis
Allele and genotype frequencies of the K variant and pheno-
type frequencies of the CHE2 locus were obtained by direct counting
and compared between groups with χ2 test with assistance of the
Clump program (Clump Sham and Curtis, 1995). Kolmogorov–
Smirnov test was used to test for normality of variables distribution.
The comparisons between means were performed by t-test (para-
metric variables) or by Mann–Whitney test (non- parametric
variables). Multiple regression analysis was performed to evaluate
the independent effect of variables. A 5% level of signiﬁcance was
adopted for all the statistical analyses performed.
3. Results
3.1. Sample characterization
Patients and elderly control characteristics are shown in Table 1.
Women–men ratios were similar in patient and control group
(χ2 = 2.53, p = 0.11). The patient group was a compound of 52 men
and 87 women. In the rivastigmine treated patient group (n = 37),
all individuals treated with this drug were included. In the no-
rivastigmine treated group (n = 99), all patients who were not taking
this drug, while under treatment with another type of ChEI or
memantine, were included. The CDR groups analyzed were
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age-homogeneous (CDR1 = 71.2 ± 8.21; CDR2 = 72.3 ± 11.23;
CDR3 = 72.2 ± 9.02).
3.2. Case–control study: AD patients × elderly controls
Table 2 shows that mean total BChE activity in plasma was sig-
niﬁcantly higher in elderly controls (6.45 KU/L ± 1.49) than in patients
with AD (5.52 KU/L ± 1.54; t = 5.17, p = 4.49 × 10−7) as the relative
mean activity of G4, G1-ALB and G1 bands. Mean total BChE activ-
ity and relative activity of G4 and G1 BChE bands remained
signiﬁcantly lower in patients than in controls even when only no-
rivastigmine treated patients were considered (p = 0.0016; p = 0.0056;
p = 0.0095, respectively). The reduction in BChE activity did not occur
proportionally in all molecular forms, since the dimer showed no
signiﬁcant difference in activity in patients and controls.
Frequencies of loco CHE2 phenotypes and of carriers of the K allele
were similar between patients and controls (χ2 = 0.46, p = 0.50 and
χ2 = 0.63, p = 0.43, respectively). The genotype distributions were in
Hardy–Weinberg equilibrium.
Since mean total BChE activity was signiﬁcantly higher in the
control group than in the AD patient group, a multiple regression
analysis was conducted considering AD presence, sex, CHE2 phe-
notype, K variant presence and rivastigmine treatment as
independent variables and total BChE activity as the dependent vari-
able. These results conﬁrmed that AD and K variant are independent
factors for decreasing total BChE activity in plasma (β = 0.29 ± 0.06,
p = 2.43 × 10−6; β = 0.19 ± 0.06, p = 0.0018, respectively).
Whereas signiﬁcant difference was found between the means of
molecular forms activity in patients and controls, it was con-
ducted another regression analysis considering eachmolecular form
as a dependent factor. Thus, about G1 and G1-ALB, both AD and K
variant act as independent factors in the decrease of activity. On
the other hand, considering G4 as the dependent variable, only AD
is a signiﬁcant factor in the decrease of tetramer activity
(β = 0.28 ± 0.06, p = 7.09 × 10-6). Regarding the dimer, only K variant
acts in the decrease of this molecular form activity (β = −0.17 ± 0.06,
p = 0.0053).
3.3. Patients study: rivastigmine treated × no-rivastigmine treated
and AD progression
Table 3 shows means of MMSE score, total BChE activity and rel-
ative activities of BChE bands (G4, G2, G1-ALB and G1) in each CDR
group. The means of MMSE score were signiﬁcantly different
between CDR1 and CDR2 (t = 5.71; p = 1.37 × 10−7); CDR1 and CDR3
(t = 14.83; p = 1.5 × 10−25) and CDR2 and CDR3 (t = 8.31;
p = 1.23 × 10−12). Means of ATV were signiﬁcantly different only
between CDR1 and CDR3 (t = 2.47; p = 0.015) and the same was true
for means of relative activity of G4 (t = 2.47; p = 0.016) and G1
(t = 2.61; p = 0.011).
Mean total BChE activity andmean relative activity of G4, G2 and
G1-ALB BChE bands were signiﬁcantly higher in the no-rivastigmine
treated patients than in the rivastigmine-treated patients. Themeans
of MMSE scores were not different between rivastigmine-treated
and no-rivastigmine treated patients (Table 4).
There were no signiﬁcant differences in total BChE activity and
mean MMSE scores between rivastigmine-treated and no-
rivastigmine treated patients in CDR1 and CDR3 groups. However,
in the CDR2 group, the mean total BChE activity was signiﬁcantly
lower in the rivastigmine-treated patients (4.28 KU/L ± 1.19) than
no-rivastigmine treated patients (6.07 KU/L ± 1.50; t = 3.98,
p = 0.0003) (Table 5) as the relative activities of all BChE molecu-
lar forms (Table 6).
Since mean total BChE activity was different among CDRs groups
and between rivastigmine-treated and no-rivastigmine treated pa-
tients, a multiple regression analysis was conducted considering
CDR, sex and rivastigmine treatment as independent variables
and total BChE activity as the dependent variable. This analysis
conﬁrmed that CDR acts as an independent factor in the decrease
of total plasma BChE activity (β = 0.21 ± 0.09, p = 0.0259). Consid-
ering G4 and G1 as dependent variables, similar results were
obtained.
Table 1
Means ± standard deviations (S.D.) for age, years of schooling and Mini Mental State
Examination (MMSE) scores in patients and controls and p values for comparisons
between means.
Patients
n = 139
Controls
n = 139
p2
Mean ± S.D. Mean ± S.D.
Age1 72.16 ± 9.54 71.17 ± 8.08 0.37
Years of schooling 5.99 ± 5.08 7.13 ± 4.9 0.06
MMSE 14.33 ± 8.29 27.09 ± 2.39 0.00
1 Patient’s age was determined according to the age of onset of AD symptoms
(n = 116).
2 t-test for parametric variable; Mann–Whitney U test for non-parametric variable.
Table 2
Means ± standard deviations (S.D.) and p value of total BChE activity (ATV) and rel-
ative activity of BChE bands (G4, G2, G1-ALB and G1) in patients and controls.
Patients
n = 139
Controls
n = 139
p (t-test)
Mean (KU/L) ± S.D. Mean (KU/L) ± S.D.
ATV 5.52 ± 1.54 6.45 ± 1.49 4.49 × 10−7
G4 3.24 ± 0.93 3.78 ± 1.06 9.17 × 10−6
G2 0.77 ± 0.36 0.84 ± 0.54 0.1100
G1 – ALB 0.73 ± 0.38 0.87 ± 0.39 0.0028
G1 0.78 ± 0.45 0.97 ± 0.49 0.0008
Table 3
Means ± standard deviations (S.D.) of MMSE scores, total BChE activity (ATV) (KU/L)
and relative activity of BChE bands (G4, G2, G1-ALB and G1) (KU/L) within each CDR
patient group.
CDR1
n = 48
CDR2
n = 47
CDR3
n = 41
Mean ± S.D. Mean ± S.D. Mean ± S.D.
MMSE 21.23 ± 4.79 15.11 ± 5.64 5.37 ± 5.30
ATV 5.88 ± 1.39 5.54 ± 1.63 5.11 ± 1.56
G4 3.39 ± 0.93 3.33 ± 1.02 2.94 ± 0.77
G2 0.79 ± 0.32 0.74 ± 0.40 0.79 ± 0.38
G1-ALB 0.77 ± 0.35 0.73 ± 0.41 0.70 ± 0.38
G1 0.93 ± 0.47 0.74 ± 0.41 0.67 ± 0.46
Table 4
Means ± standard deviations (S.D.) of total BChE activity (ATV), relative activity of
BChE bands (G4, G2, G1-ALB and G1) and MMSE score in rivastigmine-treated pa-
tients (RVG) and no-rivastigmine treated patients (No-RVG).
RVG
n = 37*
NO-RVG
n = 99*
p (t-test)
Mean (KU/L) ± S.D. Mean (KU/L) ± S.D.
MMSE 14.27 ± 8.18 14.47 ± 8.34 0.90
ATV 4.76 ± 1.52 5.84 ± 1.45 0.0002
G4 2.82 ± 0.85 3.41 ± 0.92 0.0009
G2 0.64 ± 0.30 0.82 ± 0.37 0.0067
G1 – ALB 0.59 ± 0.35 0.79 ± 0.38 0.0054
G1 0.72 ± 0.54 0.82 ± 0.42 0.2600
* In the “Patients study”, the total number of patients was 136 because there was
no information on the treatment for all 139.
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4. Discussion
The evidence of the BCHE knockout mouse has an essentially
normal phenotype (Li et al., 2000; Mesulam et al., 2002) and that
numerous human BChE mutations, many that silence the enzyme
with minimal physiological effect, suggest that the enzyme may be
redundant. However, according to Johnson and Moore’s (2012)
review, structurally and functionally, BChE is neither a vestigial nor
a degenerate AChE, but a unique enzyme with detoxiﬁcation and
synaptic eﬃciency. Phylogenetic analysis of BChE and AChE expres-
sion indicates that these two enzymes have emerged from a common
precursor whose function was to hydrolyze acetylcholine. There-
fore, the ACHE and BCHE genes arose by gene duplication after the
emergence of cholinergic systems (Chatonnet and Lockridge, 1989;
Hall and Spierer, 1986; Pritchard et al., 1994; Toutant, 1989). Thus,
BCHE appears to be a good example of a gene that has survived by
subfunctionalization, the proposal in which two genes, original and
duplicate, split the functions of the original gene between them
(Johnson and Moore, 2012).
It is noteworthy that BChE is found in the central and periph-
eral nervous systems and it is the major ACh hydrolyzing enzyme
in plasma (Lampón et al., 2012) which is virtually free of AChE
(Brimijoin and Hammond, 1988). BChE levels in the body exceed
those of AChE in all tissues except muscle and brain (Li et al., 2000).
The human body contains ten times more molecules of BChE than
AChE (Manoharan et al., 2007). In the Alzheimer’s disease, acetyl-
cholinesterase is lost up to 85% in speciﬁc brain regions, whereas
butyrylcholinesterase levels, chieﬂy the G1 form, rise with disease
progression (Arendt et al., 1992; Perry et al., 1978).
Our results showed that there is a reduction in total plasma BChE
activity in AD patients when compared to elderly controls (Table
2). Furthermore, we also found that there is a reduction in the total
plasma BChE activity with the AD progression as well as in theMMSE
scores in AD patients. The decrease in total BChE activity was par-
ticularly signiﬁcant betweenmild (CDR1) and severe AD stage (CDR3)
patient groups (Table 3). Interestingly, the regression analysis results
showed that AD is the main factor that inﬂuences the BChE activ-
ity in the case–control study, and the stage of disease (CDR) is the
main factor that acts further reducing the plasma activity of this
enzyme among patients. This fact highlights that Alzheimer’s disease
is the ﬁrst element that alters the homeostasis of the peripheral BChE
activity while the evolution of the disease is the second one that
exacerbates this decline in patients.
These results may be explained by BChE kinetic response to con-
centrations of ACh. It is known that BChE is less eﬃcient in ACh
hydrolysis at low concentrations but highly eﬃcient at higher ones,
a situation in which AChE becomes substrate inhibited (Silver, 1974).
Considering that AD is characterized by a cholinergic neuron loss
and a progressive decline in acetylcholine (ACh) levels, the periph-
eral higher BChE activity becomes unnecessary in this condition,
remaining at lower levels by a feedback mechanism. This hypoth-
esis is supported by the fact that the activity of this enzyme is
reduced peripherally with disease progression while high levels are
progressively found in the brain with AD. According to Giacobini
et al. (2002), the absolute levels of BChE activity in plasma and CSF
(cerebrospinal ﬂuid) were not signiﬁcantly associated. This sug-
gests that the BChE activity and its changes measured in CSF of AD
patients does not have its origin from plasma, but most likely from
the brain, presumably as a consequence of the higher BChE activ-
ity found in the brain of AD patients.
Additionally, we found that the decrease in the activity of BChE
in patients was not homogeneously distributed to all molecular
forms. We observed a signiﬁcant reduction in G4, G1 and G1-ALB
relative activities, but this did not occur with the G2 band (Table
2). Similarly, we found that this reduction was also not homoge-
neous when considering disease progression in patients. In this case,
there were no signiﬁcant reductions in the relative activity of G2
and G1-ALB between CDR1 and CDR3 patient groups (Table 3). These
results differ from those of Boberg et al. (2010) and Silva et al. (2012)
who reported a homogeneous reduction of all molecular forms, in
a case–control study with obese and in a physical exercise
intervention study with obese adolescents, respectively. Consider-
ing the different results found in the present study, it is possible that
AD interferes in the regulation of proportionality between the rel-
ative activities of BChE molecular forms, which may further affect
the role of this enzyme in the peripheral cholinergic system in AD
progression.
Whereby BChE activity appears to be involved in the transfor-
mation of Aβ plaques from a benign diffuse state to the compact
malignant form (Guillozet et al., 1997), non-selective inhibition may
therefore help to slow down the formation of these plaques in AD
patients’ brain (Giacobini, 2000). Evidence suggests that inhibi-
tion of both AChE and BChE by rivastigmine may be beneﬁcial in
treating the cognitive decline of AD (Giacobini et al., 2002) andmight
have the potential to provide the greatest long-term beneﬁts
(Darreh-Shori and Soininen, 2010).
Activities of AChE in CSF and of BChE in plasma and CSF are
stronglyinhibited by rivastigmine, and this inhibition is associated
with improved cognitive performance (Giacobini et al., 2002). Sim-
ilarly, the Darreh-Shori et al. (2002) study veriﬁed that rivastigmine
causes persistent inhibition of AChE and BChE in CSF (by 36% for
AChE and 45% for BChE) as well as plasma (27% for AChE and 33%
for BChE) in eleven patients with mild AD. We found that patients
Table 5
Means ± standard deviations (S.D.) of MMSE and total BChE activity (ATV) in rivastigmine-treated patients (RVG) and no-rivastigmine treated patients (No-RVG) within each
CDR group.
CDR1
n = 48*
CDR2
n = 47*
CDR3
n = 41*
ATV (KU/L) MMSE ATV (KU/L) MMSE ATV (KU/L) MMSE
RVG 5.51 ± 1.36 22.5 ± 4.97 4.28 ± 1.19 15.71 ± 3.89 4.65 ± 1.88 5.75 ± 5.59
No-RVG 6.00 ± 1.41 20.92 ± 4.82 6.07 ± 1.50 14.85 ± 6.28 5.39 ± 1.39 5.18 ± 5.24
p (t-test) 0.3352 0.3650 0.0003 0.6356 0.1768 0.7625
* In the “Patients study”, the total number of patients was 136 because there was no information on the treatment for all 139.
Table 6
Means ± standard deviations (S.D.) of relative activity of the BChE bands (G4, G2, G1-
ALB AND G1) in rivastigmine-treated patients (RVG) and no-rivastigmine treated
patients (No-RVG) within the CDR2 group. All BChE bands activities are presented
in KU/L.
CDR2
n = 47
RVG
n = 14
No-RVG
n = 33
p (t-test)
G4 2.82 ± 0.88 3.55 ± 1.01 0.0235
G2 0.46 ± 0.27 0.86 ± 0.38 0.0009
G1- ALB 0.46 ± 0.21 0.84 ± 0.43 0.0023
G1 0.55 ± 0.28 0.83 ± 0.43 0.0323
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treated with rivastigmine have total BChE and G4, G2 and G1-ALB
activities signiﬁcantly lower comparedwith patients not treatedwith
this inhibitor (Table 4), conﬁrming the action of this drug on the
plasma BChE activity.
We found a signiﬁcant reduction in plasma BChE activity in the
CDR2 group rivastigmine treated patients when compared with no-
rivastigmine treated ones (Table 5). Similar results occurred with
the relative activity of all the molecular forms of BChE in the CDR2
group (Table 6). These ﬁndings suggest that a stronger rivastigmine
effect is observed in patients with moderate AD than in mild and
severe stage patients. The peripheral BChE inhibition was not cor-
related with changes of performance in speed/attention- and
memory-related tasks (Giacobini et al., 2002) but the common side
effects (nausea, gastrointestinal upset, and diarrhea) observed due
to ChEIs acting in the peripheral nervous system are most notable
for rivastigmine (Bullock et al., 2006; Casey et al., 2010). Also, our
results show that the side effects may be intensiﬁed in the CDR2
patient group just because the rivastigmine peripheral action seems
to be more intense than in CDR1 and CDR3 groups. The reduction
in BChE activity observed in the moderate phase is a relevant clin-
ical ﬁnding, whereas the cholinergic signaling is involved in
peripheral homeostasis through activation of the parasympa-
thetic system andmediating both neuromuscular and inﬂammatory
responses (Ofek and Soreq, 2013).
The BChE-K (K variant) is characterized by the substitution A539T
in the tetramerization domain of the enzyme. Primarily, it was as-
sociatedwith 33% reduction of BChEmolecules in plasma (Rubinstein
et al., 1978) and with a 30% decreased capacity of hydrolyzing
butyrylthiocholine (Bartels et al., 1992). However, Altamirano et al.
(2000) reported that BChE-K demonstrates no apparent differ-
ences from wild-type BChE and this mutation does not affect
hydrolytic activity neither tetramer formation. According to Podoly
et al. (2009) BChE-K is inherently unstable and shows impaired
quaternary organization when compared with the wild-type, re-
sulting in reduced hydrolytic activity and predicting prolonged
acetylcholine maintenance and protection from AD. However, other
ﬁndings demonstrated that K variant was considerably less effec-
tive in attenuating the accumulation of Aβ ﬁbrils than BChE wild-
type (Diamant et al., 2006). Thus, this variant may pose either a
risk or a protective factor in AD (Podoly et al., 2009). This study
found no association between the K variant and AD, similar to the
study of Simão-Silva et al. (2013) in a southeastern Brazilian pop-
ulation. The debate of the BChE function on AD neuropathology
was accompanied by several studies that aimed to verify associa-
tion between BChE-K and Alzheimer’s disease. Some of them found
the BCHE-K was associated with AD (Lehmann et al., 1997; McIlroy
et al., 2000; Raygani et al., 2004; Tilley et al., 1999; Wiebusch et al.,
1999) and others found no association (Alvarez-Arcaya et al., 2000;
Ki et al., 1999; Singleton et al., 1998). Bizzarro et al. (2010), in turn,
suggest a protective effect of K variant, since the authors found it
in a lower frequency in AD patients when compared to healthy
controls and to fronto-temporal dementia (FTD) patients. In con-
trast to Podoly et al. (2009), in the present study it was veriﬁed
that the K variant acts by reducing G2, G1 and G1-ALB relative
activities and not the tetramer (G4), which suffered greater inﬂu-
ence of AD itself.
In conclusion, we demonstrated that there is lower total plasma
BChE activity in AD patients than in elderly controls and that the
reduction on plasma BChE activity is associated directly with AD
progression. Thus, this work shows evidence that AD acts as a main
factor in lowering plasma BChE activity and that severe stages are
related with an even greater reduction. Another interesting ﬁnding
was the fact that rivastigmine showed a stronger effect in reduc-
ing peripheral BChE activity in patients with moderate AD, which
are, therefore, more likely to suffer side effects. Furthermore, we ob-
served that the reduction of relative activity of BChEmolecular forms
was not homogeneous. The failure to maintain proportionality
betweenmolecular forms of BChE in ADmay suggest that the disease
interferes in the homeostasis regulation and may further affect the
role of this enzyme in the peripheral cholinergic system.We propose
that plasma BChE activity may be used as a secondary marker in
AD, and that periodic measurement of peripheral BChE activity may
be useful for evaluating AD progression, especially as this is an as-
sessment that lacks side effects.
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